Skip to main content
SpringerLink
Log in

Impressive results with donepezil in Alzheimer’s disease

  • Newsletter Article
  • Published:
Inpharma Weekly

Abstract

A pivotal phase III trial of the selective cholinesterase inhibitor donepezil [E-2020; Eisai] has shown that the drug significantly improves cognition and daily functioning in patients with mild-to-moderate Alzheimer’s disease. The results also indicate that donepezil has a good tolerability profile, with no signs of the adverse hepatotoxic effects seen with tacrine. The study findings were presented at the 5th International Conference on Alzheimer’s Disease and Related Disorders [ Osaka, Japan; July 1996 ].

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Authors
  1. Jill Stein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stein, J. Impressive results with donepezil in Alzheimer’s disease. Inpharma Wkly. 1053, 9–10 (1996). https://doi.org/10.2165/00128413-199610530-00017

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128413-199610530-00017

Keywords

Search

Navigation